Literature DB >> 27270029

Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.

Alex Cortez1, Yongkai Li1, Andrew T Miller1, Xiaoyue Zhang1, Kathy Yue1, Jillian Maginnis1, Janice Hampton1, De Shon Hall1, Michael Shapiro1, Bishnu Nayak1, Ugo D'Oro2, Chun Li1, David Skibinski2, M Lamine Mbow3, Manmohan Singh3, Derek T O'Hagan3, Michael P Cooke1, Nicholas M Valiante3, Tom Y-H Wu1.   

Abstract

Small molecule Toll-like receptor 7 (TLR7) agonists have been used as vaccine adjuvants by enhancing innate immune activation to afford better adaptive response. Localized TLR7 agonists without systemic exposure can afford good adjuvanticity, suggesting peripheral innate activation (non-antigen-specific) is not required for immune priming. To enhance colocalization of antigen and adjuvant, benzonaphthyridine (BZN) TLR7 agonists are chemically modified with phosphonates to allow adsorption onto aluminum hydroxide (alum), a formulation commonly used in vaccines for antigen stabilization and injection site deposition. The adsorption process is facilitated by enhancing aqueous solubility of BZN analogs to avoid physical mixture of two insoluble particulates. These BZN-phosphonates are highly adsorbed onto alum, which significantly reduced systemic exposure and increased local retention post injection. This report demonstrates a novel approach in vaccine adjuvant design using phosphonate modification to afford adsorption of small molecule immune potentiator (SMIP) onto alum, thereby enhancing co-delivery with antigen.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270029     DOI: 10.1021/acs.jmedchem.6b00489

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  A new computational model for the prediction of toxicity of phosphonate derivatives using QSPR.

Authors:  Rosa L Camacho-Mendoza; Eliazar Aquino-Torres; Viviana Cordero-Pensado; Julián Cruz-Borbolla; José G Alvarado-Rodríguez; Pandiyan Thangarasu; Carlos Z Gómez-Castro
Journal:  Mol Divers       Date:  2018-03-12       Impact factor: 2.943

2.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

3.  Interfacial engineering of renewable metal organic framework derived honeycomb-like nanoporous aluminum hydroxide with tunable porosity.

Authors:  Ye-Tang Pan; Lu Zhang; Xiaomin Zhao; De-Yi Wang
Journal:  Chem Sci       Date:  2017-02-28       Impact factor: 9.825

4.  Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.

Authors:  Hoa Thi My Vo; Barbara Christiane Baudner; Stefano Sammicheli; Matteo Iannacone; Ugo D'Oro; Diego Piccioli
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

Review 5.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

Authors:  Harm HogenEsch; Derek T O'Hagan; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-10-10       Impact factor: 7.344

6.  A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model.

Authors:  Yunlong Hu; Li Tang; Zhengyu Zhu; He Meng; Tingting Chen; Sheng Zhao; Zhenchao Jin; Zhulin Wang; Guangyi Jin
Journal:  J Transl Med       Date:  2020-03-04       Impact factor: 5.531

7.  A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.

Authors:  Floriane Auderset; Elodie Belnoue; Beatris Mastelic-Gavillet; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 8.  Emerging concepts in the science of vaccine adjuvants.

Authors:  Bali Pulendran; Prabhu S Arunachalam; Derek T O'Hagan
Journal:  Nat Rev Drug Discov       Date:  2021-04-06       Impact factor: 84.694

9.  Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.

Authors:  Shannon M Miller; Van Cybulski; Margaret Whitacre; Laura S Bess; Mark T Livesay; Lois Walsh; David Burkhart; Hélène G Bazin; Jay T Evans
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

Review 10.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.